We empower doctors and patients with leading integrated healthcare solutions to enable them to take control and reverse type 2 diabetes. Our solutions reduce and eliminate expensive direct and indirect medication and healthcare costs for healthcare organisations and patients.
Lowering Prescription Medication and Healthcare Costs
Of participants had their medications stopped
Average that resulted diabetes in remission
Average reduction in liver fat, improvement in NAFLD.
Average improvement in insulin resistance
Reduce the risk of heart attack, heart disease and stroke
and services are based on.
A low-carbohydrate, ketogenic diet to treat type 2 diabetes
The objective of the study was to investigate the effect of a low-carbohydrate, ketogenic diet (LCKD) in improving glycemia and reducing the need for medication in patients with type 2 diabetes.
24 patients were placed in the programme over a period of 180 days. Initially, patients were instructed to follow a LCKD with a goal of consuming ≤20 g carbohydrate per day. Once patients had lost half the weight required to reach their total goal, carbohydrates were slowly reintroduced into the diet by increasing the daily carbohydrate intake by approximately 5 g on a weekly basis. Furthermore, patients were advised to consume standard multivitamins and drink 6–8 glasses of water daily throughout the study.
Twenty-one of the participants completed the study and diabetes medications were discontinued in 7 participants, reduced in 10 participants, and unchanged in 4 participants. The LCKD improved glycemic control in patients with type 2 diabetes such that diabetes medications were discontinued or reduced 80% of participants. Due to the effectiveness of a LCKD in reducing blood glucose, close medical supervision should be applied to patients on this diet that may also be taking medication.
Utility of a Short-Term 25% Carbohydrate Diet on, Improving Glycemic Control in Type 2 Diabetes Mellitus
The research was undertaken to determine if introduction of a low carbohydrate diet might be a useful option for type 2 diabetic patients who do not achieve glucose target levels despite conventional treatment.
The trial consisted of 28 people with Type 2 diabetes who were unable to achieve sufficient glucose control. The cohort comprised of 9 patients that were previously treated with diet alone and 19 that were treated with oral hypoglycemic drugs (although these were discontinued at the start of the trial). The patients were placed on a diet based on ideal body weight which comprised of 25% carbohydrate. After a mean of 8 weeks, they were then switched to a caloric equivalent diet, but composed of 55% carbohydrate.
Compared to the baseline diet, after 8 weeks of a 25% of daily energy in the form of carbohydrate diet, subjects showed significantly improved glycemia as evidenced by fasting blood glucose values and hemoglobin A1c levels. Those previously treated with oral hypoglycemic agents showed a significant decrease in weight and diastolic blood pressure despite the discontinuation of the oral agent. However, when they switched back to the so-called ‘healthy’ 55% carbohydrate diet, their glucose control worsened again and their haemoglobin A1c level rose significantly over the following 12 weeks.
Therefore, a low carbohydrate and calorie-restricted diet has beneficial short-term effects in subjects with type 2 who have failed either diet or sulfonylurea therapy which may obviate the necessity for insulin.
The objective of the study was to investigate the effects of a low-calorie diet on type 2 diabetes with the goal of remission within these patients.
Individuals aged 20–65 years were recruited who had been diagnosed with type 2 diabetes within the past 6 years, had a body-mass index of 27–45 kg/m² and were not taking insulin. The intervention comprised withdrawal of antidiabetic and antihypertensive drugs with total diet replacement (825–853 kcal/day formula diet for 3–5 months) with a stepped food reintroduction that lasted 2–8 weeks.
306 individuals were recruited from 49 intervention (n=23) and control (n=26) general practices; 149 participants per group comprised the intention-to-treat population. At 12 months, weight loss of 15 kg or more in 36 (24%) participants in the intervention group and no participants in the control group (p < 0•0001) was recorded. Diabetes remission was achieved in 68 (46%) participants in the intervention group and six (4%) participants in the control group.
Diabetes remission activation serviceTM
- Detailed body scan
- Personal Healthcare report
- Planning and preperation
- Food and medication
- Monitoring services
- Nutritional and medical support
- Motivational assistance
- Personalised around individual
- Blood tests
Diabetes remission maintenance serviceTM
- Body scan reviews / updates
- Healthcare report reviews
- Reintroduction of carbs service
- Alternative food supply and guidance
- Carb food alternatives
- Medication reviews
- Exercise planning
- On going monitoring
- Regular blood monitoring
Specially designed diabetes remission programmes developed to help you at each stage to guarantee long term health improvement and lower healthcare costs.